# Nymox Pharmaceutical Corp

Nymox Pharmaceutical Corp is an other based in Havre de Grace, United States.

## Overview

- **Organization type:** other
- **Headquarters:** Havre de Grace, United States
- **Region:** North America
- **Address:** Havre de Grace, MD, United States
- **Assets under management:** Undisclosed
- **Website:** nymox.com

## Regulatory record

- **Reports private funds:** No

## About

Nymox Pharmaceutical Corp was incorporated in 1989 by Paul Averback, a pathologist who previously founded Diagnostic Cytology Laboratories. The company is headquartered in Havre de Grace, Maryland, and has focused on developing therapeutic candidates targeting age-related conditions, including benign prostatic hyperplasia (BPH) and Alzheimer's disease. Nymox's primary product candidate is NX-1207, a drug administered via intraprostatic injection for BPH. The company has also explored NX-210 for Alzheimer's disease, though development has lagged behind NX-1207. The pipeline is exclusively pharmaceutical, with no disclosed venture capital or co-investment strategy. Operations are primarily US-based, with a Danish subsidiary (Nymox Pharma A/S) that has historically supported European clinical trials. The firm is publicly traded on the NASDAQ under the ticker NYMX. It has a small team of fewer than ten full-time employees, as disclosed in SEC filings. Team size and deployment are constrained by the firm's market capitalization and cash position, which have fluctuated over the years. The company maintains no philanthropic foundations or adjacent investment vehicles. A structural differentiator is Nymox's razor-thin operation; the company has spent decades developing a single drug candidate without diversifying into other therapeutic areas or diagnostic tools. That narrow focus has created a high-conviction, high-risk profile that differs from larger pharmaceutical companies and biotech asset managers alike.

## Sectors

- Pharmaceuticals
- Healthcare Services
- Biotechnology

## People

- Paul Averback — CEO & Founder

## Questions

### How does Nymox Pharmaceutical Corp source proprietary deal flow?

The firm does not operate as an investment firm; it is a pharmaceutical development company. Its pipeline is entirely internal, originating from Dr. Averback's own research and patents. No external deal flow has been disclosed.

### What investment stages does Nymox typically target?

The firm does not invest in external companies. It develops its own drug candidates from early discovery through late-stage clinical trials, with NX-1207 currently in Phase III trials for BPH (per SEC filings).

### Does Nymox participate in fund commitments or only direct deals?

Nymox does not participate in fund commitments. It directs all capital into its own R&D pipeline, including clinical trials and regulatory activities.

### Which sectors does Nymox explicitly avoid?

The firm has not publicly stated explicit sector avoidance, but its disclosed pipeline has been limited to age-related conditions — specifically BPH and Alzheimer's — over its entire history.

## Related profiles

- [Psyence Biomedical Ltd.](https://altss.com/profile/psyence-biomedical-ltd)
- [Big Tree Cloud Holdings](https://altss.com/profile/big-tree-cloud-holdings-ltd)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/nymox-pharmaceutical-corp

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology